Emergent Biosolutions (NYSE:EBS) Downgraded to Hold at ValuEngine

Emergent Biosolutions (NYSE:EBS) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Thursday, ValuEngine reports.

Several other analysts also recently issued reports on EBS. Cowen reiterated a “hold” rating and issued a $67.00 price target on shares of Emergent Biosolutions in a report on Thursday, November 7th. Guggenheim began coverage on Emergent Biosolutions in a report on Thursday, September 12th. They issued a “buy” rating and a $65.00 price target for the company. Laidlaw set a $72.00 price target on Emergent Biosolutions and gave the company a “buy” rating in a report on Wednesday, September 4th. TheStreet upgraded Emergent Biosolutions from a “c” rating to a “b” rating in a report on Wednesday, November 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $71.00 price target on shares of Emergent Biosolutions in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and an average price target of $69.00.

NYSE EBS traded down $0.47 during trading hours on Thursday, hitting $54.35. The company had a trading volume of 208,600 shares, compared to its average volume of 446,239. Emergent Biosolutions has a fifty-two week low of $39.11 and a fifty-two week high of $73.89. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of 23.33, a P/E/G ratio of 0.88 and a beta of 1.55. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.54 and a quick ratio of 1.71. The firm’s 50 day moving average is $54.58 and its 200 day moving average is $48.13.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.58. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The firm had revenue of $311.80 million during the quarter, compared to the consensus estimate of $289.16 million. During the same period in the prior year, the firm earned $0.55 EPS. The firm’s quarterly revenue was up 79.6% compared to the same quarter last year. On average, equities analysts anticipate that Emergent Biosolutions will post 3.08 EPS for the current year.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,509 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $56.12, for a total value of $84,685.08. Following the completion of the transaction, the director now directly owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kathryn C. Zoon sold 3,082 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $54.15, for a total transaction of $166,890.30. Following the completion of the transaction, the director now directly owns 18,412 shares of the company’s stock, valued at $997,009.80. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Vaughan Nelson Investment Management L.P. boosted its position in Emergent Biosolutions by 18.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 677,628 shares of the biopharmaceutical company’s stock valued at $35,426,000 after buying an additional 106,219 shares during the last quarter. Boston Advisors LLC boosted its position in Emergent Biosolutions by 84.6% in the 3rd quarter. Boston Advisors LLC now owns 57,003 shares of the biopharmaceutical company’s stock valued at $2,980,000 after buying an additional 26,122 shares during the last quarter. Tygh Capital Management Inc. boosted its position in Emergent Biosolutions by 211.1% in the 3rd quarter. Tygh Capital Management Inc. now owns 298,488 shares of the biopharmaceutical company’s stock valued at $15,605,000 after buying an additional 202,527 shares during the last quarter. Eagle Asset Management Inc. boosted its position in Emergent Biosolutions by 1.8% in the 3rd quarter. Eagle Asset Management Inc. now owns 312,224 shares of the biopharmaceutical company’s stock valued at $16,323,000 after buying an additional 5,592 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Emergent Biosolutions by 17.5% in the 3rd quarter. SG Americas Securities LLC now owns 3,612 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 538 shares during the last quarter. 85.57% of the stock is owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Recommended Story: Options Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.